Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$104.30 USD

104.30
113,089

-4.69 (-4.30%)

Updated Aug 1, 2024 04:00 PM ET

After-Market: $104.41 +0.11 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly Inks Deal to Include Dexcom Products in Diabetes System

by Zacks Equity Research

Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.

    Catalyst Initiates Phase II Study for Pipeline Drug Firdapse

    by Zacks Equity Research

    Catalyst (CPRX) announces the initiation of phase II study to evaluate safety, tolerability and efficacy of its lead pipeline candidate, Firdapse.

      Valeant Closes Senior Note Offering, Reprices Term Loan

      by Zacks Equity Research

      Valeant (VRX) offered new debt and restructured old debt. The company is making efforts to repay its huge level of debt.

        Alnylam's RNAi Candidate Gains Breakthrough Therapy Status

        by Zacks Equity Research

        Alnylam (ALNY) announced that the FDA has granted Breakthrough Therapy Designation for RNAi therapeutic candidate, patisiran.

          Can Valeant (VRX) Turn Around on Rebuilding Initiatives?

          by Zacks Equity Research

          Valeant (VRX) has performed much better so far in 2017 compared to last year on the back of rebuilding initiatives.

            Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?

            by Zacks Equity Research

            Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.

              Agios Posts New Data on Glioma Candidate from Dose Expansion

              by Zacks Equity Research

              Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.

                Roche Reports Positive Data From Tecentriq Combination Study

                by Zacks Equity Research

                Roche (RHHBY) announced encouraging results from IMpower150 study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel), with or without Avastin.

                  Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease

                  by Zacks Equity Research

                  Ultragenyx (RARE) clinches an FDA approval for rhGUS, a treatment option of mucopolysaccharidosis VII. The company assures the drug to be available in the United States by the month-end.

                    Alnylam Starts Rolling NDA Submission for RNAi Candidate

                    by Zacks Equity Research

                    Alnylam (ALNY) has started rolling New Drug Application to the FDA for its RNAi candidate, patisiran.

                      Valeant (VRX) Announces Pricing of Senior Secured Notes

                      by Zacks Equity Research

                      Valeant (VRX) prices its senior secured notes. The proceeds of the notes will be used to pay down its existing debt.

                        Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee

                        by Zacks Equity Research

                        Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.

                          Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin

                          by Zacks Equity Research

                          Theravance (TBPH) submits the NDA for its key candidate, revefenacin, to the FDA for treating adults with chronic obstructive pulmonary disease.

                            Shire Gets Positive CHMP Opinion for Hemophilia A Drug

                            by Zacks Equity Research

                            Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

                              Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA

                              by Zacks Equity Research

                              Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.

                                Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis

                                by Zacks Equity Research

                                CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.

                                  Vertex Gets CHMP Recommendation for Orkambi Label Expansion

                                  by Zacks Equity Research

                                  Vertex (VRTX) received CHMP recommendation for label expansion of Orkambi in children aged 6 to 11 years with CF who have two copies of the F508del mutation.

                                    Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study

                                    by Zacks Equity Research

                                    Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.

                                      Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion

                                      by Zacks Equity Research

                                      Seattle Genetics received an approval from the FDA for an expanded indication of its drug Adcetris a month before its action date.

                                        AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

                                        by Zacks Equity Research

                                        AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.

                                          Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak

                                          by Zacks Equity Research

                                          Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.

                                            BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates

                                            by Zacks Equity Research

                                            BioDelivery (BDSI) reports narrower-than-expected loss in Q3. Revenues also surpass estimates and increase significantly year over year.

                                              Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised

                                              by Zacks Equity Research

                                              Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.

                                                Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss

                                                by Zacks Equity Research

                                                Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.

                                                  Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss

                                                  by Zacks Equity Research

                                                  Intrexon (XON) reported narrower-than-expected loss but revenues missed estimates in the third quarter of 2017. The company remains focused on the development of its pipeline candidates.